Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06562777 | Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer | recruiting | — | 100 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06694480 | Study of FID-022 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 24 | Fulgent Pharma LLC.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07408258 |
| Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors |
| recruiting |
| Phase 1 |
| 20 |
| OncoC4, Inc.INDUSTRY |
| 1 |
| Sep 8, 2026 |
| clinicaltrials |
| NCT07446855 | Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours(PARTHENON) | recruiting | Phase 1 / Phase 2 | 180 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT07703878 | A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors | recruiting | Phase 1 | 302 | Gilead SciencesINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07750132 | Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 72 | Beijing StarMab Biomed Technology LtdINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07805083 | Community Enhanced Virtual Informed Consent(CEVIC) | recruiting | N/A | 600 | Mayo ClinicOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806175 | A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 486 | Rongchang Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04243499 | First-in-Human Study of ICT01 in Patients With Advanced Cancer(EVICTION) | active not recruiting | Phase 1 / Phase 2 | 293 | ImCheck Therapeutics, an Ipsen companyINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT04409236 | Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking | active not recruiting | N/A | 427 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04589845 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | active not recruiting | Phase 2 | 920 | Hoffmann-La RocheINDUSTRY | 23 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05108298 | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials | active not recruiting | Early Phase 1 | 500 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05315700 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | recruiting | Phase 1 / Phase 2 | 350 | ORIC PharmaceuticalsINDUSTRY | 10 | Sep 4, 2026 | clinicaltrials |
| NCT05372614 | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05688605 | A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 18 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06014502 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | recruiting | Phase 1 | 105 | ImmunoGenesisINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06076291 | An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors(CSG-1827-101) | completed | Phase 1 | 19 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06295367 | Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) | active not recruiting | N/A | 760 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 4, 2026 | clinicaltrials |
| NCT06311214 | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) | recruiting | Phase 2 | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06364410 | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors | recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06499350 | A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 33 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06644755 | First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Daiichi SankyoINDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT06980506 | MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer | temporarily not available | — | — | Monopar TherapeuticsINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06980519 | MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer | temporarily not available | — | — | Monopar TherapeuticsINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | recruiting | Phase 1 / Phase 2 | 480 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07361562 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Cogent Biosciences, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07412002 | Quality of End-of-Life Care for Children With Cancer | recruiting | — | 2,425 | Children's Oncology GroupNETWORK | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07678970 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 10 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07718165 | A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 | 247 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03313778 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors(KEYNOTE-603) | active not recruiting | Phase 1 | 161 | ModernaTX, Inc.INDUSTRY | 4 | Sep 3, 2026 | clinicaltrials |
| NCT05518045 | A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 392 | LaNova Medicines LimitedINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06271837 | A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | active not recruiting | Phase 2 | 127 | AstraZenecaINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06500377 | Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors | suspended | N/A | 44 | City of Hope Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06771739 | A Pilot Unrestricted Payment Program for Early-stage Cancer Patients: the PAYMENT Trial | recruiting | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07358260 | B7-H3.CD28Z.CART in Solid Tumors | recruiting | Phase 1 | 40 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07545265 | SKB565 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03440450 | A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer | active not recruiting | Phase 1 | 90 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03739827 | Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors | recruiting | — | 10,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04047251 | A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma | active not recruiting | Phase 1 | 96 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials